TV003

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Medigen Vaccine Biologics Corp.

Conditions

Dengue

Phase 2

Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand

CompletedNCT02332733

National Institute of Allergy and Infectious Diseases (NIAID)Dengue

Start: 2014-11-30End: 2018-10-26Target: 266Updated: 2018-12-05

A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan

CompletedNCT03485144

Medigen Vaccine Biologics Corp.Dengue

Start: 2017-12-12End: 2019-05-10Updated: 2019-08-14